“…Helical polypeptides with covalently attached (via a carbon‐based linker) PC molecules (Tegler et al , 2011 ), peptide mimetics (mw > 700 Da) (Kumaresan et al , 2013 ), and anti‐sense oligonucleotides (ASO) (Warren & Flaim, n.d. ) targeting CRP have been developed, with the latter reaching phase II clinical trials (ISIS‐329993 and ISIS‐353512, NCT01710852, NCT01414101, and NCT00734240; Warren et al , 2015 ). Furthermore, reducing circulating pCRP levels via CRP apheresis using PC‐linked resins is currently being investigated with promising initial results as an adjunct therapy to minimize cardiac injury in patients with myocardial infarction (Ries et al , 2019 , 2021 ) and COVID‐19 (Pepys, 2021 ; Ringel et al , 2021 ; Schumann et al , 2021 ; Torzewski et al , 2021 ; Esposito et al , 2022 ). The therapeutic approaches discussed above target general pCRP inhibition and reduction of circulating pCRP levels.…”